about the author

Endpoints Contributor

help@endpts.com

author articles

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

6 years ago

Part­ner with the right bio­an­a­lyt­ics firm at start-up to de-risk drug de­vel­op­ment

6 years ago

Con­quer­ing a silent killer: HDV and Eiger Bio­Phar­ma­ceu­ti­cals

6 years ago

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

6 years ago

Prac­ti­cal im­pli­ca­tions of re­cent FDA guid­ance on im­muno­genic­i­ty risk as­sess­ments on your IND sub­mis­sions

6 years ago

RWE chal­lenges for to­day's bio­phar­ma

6 years ago

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

6 years ago

Novotech CRO sees 26% growth in Asia tri­al ac­tiv­i­ty from biotechs, but still plen­ty of ca­pac­i­ty

6 years ago

Lead­ing the Next CAR T Rev­o­lu­tion in Can­cer

6 years ago

Biotech boards bur­dened: Bridg­ing the suc­cess gap

6 years ago
Financing
Startups

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

6 years ago
China
Biotech Voices

Solv­ing the chal­lenge of nu­cle­ic acid de­liv­ery in RNA med­i­cines

6 years ago

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

6 years ago

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

6 years ago
R&D
Biotech Voices

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

6 years ago

How small- to mid-sized biotechs can adopt pa­tient cen­tric­i­ty in their on­col­o­gy tri­als

6 years ago

Reg­u­la­to­ry in­tel­li­gence: Up­date on re­gen­er­a­tive med­i­cine ad­vanced ther­a­pies des­ig­na­tions

6 years ago
Cell/Gene Tx

Boost­ing check­point in­hibitor ef­fi­ca­cy via the mi­cro­bio­me

7 years ago

Whale watch­ing: What a decade of change at Big Phar­ma taught us about cor­po­rate phe­no­types

7 years ago
Deals
Biotech Voices

Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

7 years ago
R&D
Biotech Voices

How the sur­gi­cal set­ting con­tributes to the opi­oid cri­sis

7 years ago

Fol­licum, a Swedish biotech com­pa­ny born to find a treat­ment for hair loss, now has di­a­betes in its crosshairs

7 years ago

Phar­ma, we have a prob­lem: New drugs can't cov­er the cost of Big Phar­ma's fail­ures

7 years ago
R&D
Biotech Voices

Cel­gene's top 20 up­front hits: Just how gen­er­ous was Cel­gene in deal­mak­ing? Let's re­view the records

7 years ago
Pharma
First page Previous page 789101112 Next page Last page
A service from the Financial Times